These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15562415)

  • 1. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.
    Dauvilliers Y; Carlander B; Rivier F; Touchon J; Tafti M
    Ann Neurol; 2004 Dec; 56(6):905-8. PubMed ID: 15562415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment.
    Dauvilliers Y; Abril B; Mas E; Michel F; Tafti M
    Neurology; 2009 Oct; 73(16):1333-4. PubMed ID: 19841387
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.
    U.S. Xyrem Multicenter Study Group
    Sleep Med; 2004 Mar; 5(2):119-23. PubMed ID: 15033130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy.
    Knudsen S; Mikkelsen JD; Bang B; Gammeltoft S; Jennum PJ
    Neuropediatrics; 2010 Oct; 41(5):217-22. PubMed ID: 21210337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Narcolepsy: a new perspective on diagnosis and treatment].
    Fronczek R; van der Zande WL; van Dijk JG; Overeem S; Lammers GJ
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):856-61. PubMed ID: 17472116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics and treatment of narcolepsy.
    Dauvilliers Y; Tafti M
    Ann Med; 2006; 38(4):252-62. PubMed ID: 16754256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.
    Prescrire Int; 2007 Jun; 16(89):98-101. PubMed ID: 17582923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1).
    Baier PC; Weinhold SL; Huth V; Gottwald B; Ferstl R; Hinze-Selch D
    Brain; 2008 Oct; 131(Pt 10):2734-41. PubMed ID: 18718966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy.
    Valko PO; Khatami R; Baumann CR; Bassetti CL
    J Neurol; 2008 Dec; 255(12):1900-3. PubMed ID: 18825431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem).
    Alshaikh MK; Gacuan D; George S; Sharif M; Bahammam AS
    Clin Neuropharmacol; 2011; 34(1):1-4. PubMed ID: 21206362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Narcolepsy: pathophysiology and pharmacology.
    Nishino S
    J Clin Psychiatry; 2007; 68 Suppl 13():9-15. PubMed ID: 18078360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the diagnosis and treatment of narcolepsy-cataplexy syndrome].
    de Vicente Alvarez-Manzaneda EE
    Rev Neurol; 2008 May 1-15; 46(9):550-6. PubMed ID: 18446698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical aspects of the narcolepsy-cataplexy syndrome].
    Hess CW; Scharfetter C; Mumenthaler M
    Nervenarzt; 1984 Aug; 55(8):391-401. PubMed ID: 6483061
    [No Abstract]   [Full Text] [Related]  

  • 15. [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].
    Poza-Aldea JJ
    Rev Neurol; 2009 Jan 1-15; 48(1):27-31. PubMed ID: 19145563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency.
    Overeem S; van Nues SJ; van der Zande WL; Donjacour CE; van Mierlo P; Lammers GJ
    Sleep Med; 2011 Jan; 12(1):12-8. PubMed ID: 21145280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Narcolepsy: treatment issues.
    Roth T
    J Clin Psychiatry; 2007; 68 Suppl 13():16-9. PubMed ID: 18078361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Childhood narcolepsy with partial facial cataplexy: a diagnostic dilemma.
    Dhondt K; Verhelst H; Pevernagie D; Slap F; Van Coster R
    Sleep Med; 2009 Aug; 10(7):797-8. PubMed ID: 19147400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy/cataplexy.
    Mattarozzi K; Bellucci C; Campi C; Cipolli C; Ferri R; Franceschini C; Mazzetti M; Russo PM; Vandi S; Vignatelli L; Plazzi G
    Sleep Med; 2008 May; 9(4):425-33. PubMed ID: 17681883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate.
    Huang YS; Guilleminault C
    Pediatr Neurol; 2009 Jul; 41(1):9-16. PubMed ID: 19520267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.